In new study led by @bblarsen1 in collab w @veeslerlab @VUMC_Vaccines we map functional & antigenic landscape of Nipah virus receptor binding protein (RBP)
Results elucidate constraints on RBP function & provide insight re protein’s evolutionary potentialbiorxiv.org/content/10.110…
Nipah is bat virus that sporadically infects humans w high (~70%) fatality rate. Has been limited human transmission
Like other paramyxoviruses, Nipah uses two proteins to enter cells: RBP binds receptor & then triggers fusion (F) protein by process that is not fully understood
RBP forms tetramer in which 4 constituent monomers (which are all identical in sequence) adopt 3 distinct conformations
RBP binds to two receptors, EFNB2 & EFNB3
RBP’s affinity for EFNB2 is very high (~0.1 nM, over an order of magnitude higher than SARSCoV2’s affinity for ACE2)
To study mutants of RBP, we used pseudovirus deep mutational scanning, which uses non-replicative lentivirions safe at BSL-2 ()
We generated pseudoviruses w all amino-acid mutants of RBP & quantified their ability to infect cells expressing EFNB2 or EFNB3 blog.addgene.org/viral-vectors-…
To ensure these safe pseudovirus experiments generated beneficial knowledge about RBP function & antigenicity but *not* potentially hazardous info () on mutations that adapt RBP to human receptors, we used cells expressing bat rather than human EFNs pubmed.ncbi.nlm.nih.gov/30419157/
Figure below shows how all amino-acid mutations to RBP affect pseudovirus entry into cells expressing bat EFNB3.
Some regions of RBP quite tolerant of mutations, but others under heavy constraint (most mutations disrupt pseudovirus cell entry)
Constraint especially high in dimerization faces & sites in neck that likely play key role in triggering F (see paper for details on specific sites)
We also measured how all functionally tolerated RBP mutations affect binding to EFNB2 vs EFNB3, & identified specific mutations that increase binding to both or just one of the bat versions of these receptors
We also measured how all RBP mutations affect neutralization by panel of antibodies.
Some antibodies (eg, nAH1.3) are escaped by many well-tolerated mutations, whereas others (eg, HENV-103) are mostly escaped only by mutations that impair RBP function.
The above finding is informative for helping select antibodies that are likely to be resistant to viral escape. However, it is notable that antigenic diversity of known Nipah viruses is low, with almost none of the escape mutations observed among natural sequences.
Overall, this study generates a huge wealth of information for understanding RBP function, receptor binding, antigenicity, and evolution.
@bblarsen1 has made a superb webpage with interactive plots that facilitate exploration of the data: dms-vep.org/Nipah_Malaysia…
Thanks to everyone who contributed to this study: @bblarsen1, Teagan McMahon, Jack Brown, Zhaoqian Wang, @CaelanRadford, @VUMC_Vaccines, and @veeslerlab
We examined spike of KP.3.1.1, a strain from late 2024 / early 2025 similar to current variants
KP.3.1.1 & other recent variants have >60 spike amino-acid mutations relative to early pandemic strains, as spike has evolved at extraordinary rate of >10 mutations/year on avg
We previously developed pseudovirus deep mutational scanning (), which uses non-replicative viral particles to safely study spike mutations.
Here we used approach to measure how mutations to KP.3.1.1 spike affect five phenotypes, as shown below. pubmed.ncbi.nlm.nih.gov/36868218/
We used pseudovirus deep mutational scanning to characterize all mutations to a recent H3N2 HA. This approach uses virions that can only undergo one round of cell entry & so are not pathogens capable of causing disease.
As can be seen below, constraint due to mutational impacts on cell entry are widely distributed across HA including receptor-binding pocket and fusion peptide. But mutational constraint due to HA stability is concentrated at trimer and HA1-HA2 interface.
In new study, we find dramatic differences in specificities of serum neutralizing antibodies in infants w single infection by a recent SARS-CoV-2 strain versus adults/children imprinted by an early viral strain.
As background, immune response to a virus is “imprinted” by first exposure, since later exposures to new viral strains often activate pre-existing B-cells.
For SARS-CoV-2, most people globally imprinted by an early viral strain from either vaccination or infection in 2020-2021.
However, small but growing fraction of population has instead been imprinted by more recent viral strain.
Specifically, we compared adults/children imprinted by original vaccine then infected w XBB* strain in 2023 vs infants only infected w XBB* in 2023.
I’ve updated SARSCoV2 antibody-escape calculator w new deep mutational scanning data of @yunlong_cao @jianfcpku
My interpretation: antigenic evolution currently constrained by pleiotropic effects of mutations on RBD-ACE2 affinity, RBD up-down position & antibody neutralization
@Nucleocapsoid @HNimanFC @mrmickme2 @0bFuSc8 @PeacockFlu @CVRHutchinson @SCOTTeHENSLEY To add to thread linked above, human British Columbia H5 case has a HA sequence (GISAID EPI_ISL_19548836) that is ambiguous at *both* site Q226 and site E190 (H3 numbering)
Both these sites play an important role in sialic acid binding specificity
@Nucleocapsoid @HNimanFC @mrmickme2 @0bFuSc8 @PeacockFlu @CVRHutchinson @SCOTTeHENSLEY If you are searching literature, these sites are E190 and Q226 in H3 numbering, E186 and Q222 in mature H5 numbering, and E202 and Q238 in sequential H5 numbering (see: )dms-vep.org/Flu_H5_America…